Geron Corporation
GERN Market Cap, Stock Price & Valuation
With a market capitalization (market cap) of $1B — a measure of how much the company is worth — Geron Corporation is the 2595th most valuable company in Healthcare as of July 9, 2026. Shares trade at $1.56, up +4.70% on the day. Over the past year its share price has moved +12.23%.
$1.56
+4.70%gain today
Market position
Market cap rank
#2595
of 2,595
1-day
+4.70%
1-month
+38.05%
6-month
+18.18%
YTD
+18.18%
1-year
+12.23%
5-year
+16.42%
Key figures
Market cap
$1B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-10.2
FY 2025
EPS
-$0.13
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.00
Gross margin
97.42%
FY 2025
Operating margin
-29.28%
FY 2025
Net margin
-46.65%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.05B
FY 2025
EV / EBITDA
-20.26
FY 2025
EV / Sales
5.72
FY 2025
Price / book
3.90
FY 2025
Price / sales
4.79
FY 2025
Earnings yield
-9.75%
FY 2025
FCF yield
-12.62%
FY 2025
Debt / equity
1.11
FY 2025
Current ratio
4.66
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$183.88M
Gross profit
$179.14M
Operating income
$-53.84M
EBITDA
$-51.92M
Net income
$-85.78M
Diluted EPS
-$0.13
Shares outstanding
666,662,989
Trading
Open
$1.47
Previous close
$1.49
Day range
$1.46 – $1.56
52-week range
$1.04 – $2.01
50-day avg
$1.33
200-day avg
$1.39
Volume
12,223,398
Avg volume
14,673,619
Beta
0.60
Price history
Compare with peers
About Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
Visit websiteCompany info
CEO
Harout Semerjian
IPO date
Jul 31, 1996
Headquarters
Foster City, CA, US
Frequently asked questions
How much is Geron Corporation worth?
As of July 9, 2026, Geron Corporation (GERN) is worth $1B — this is its market capitalization, the total value of all its outstanding shares.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $1B, which ranks it #2595 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
What is Geron Corporation’s stock price?
Geron Corporation (GERN) shares trade at $1.56, up 4.70% on the day, as of July 9, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
